modelMethylprednisoloneAndAnt

Diagram of MethylprednisoloneAndAnt

Extends from Pharmacolibrary.Drugs.ATC.S.S01CA08.

Information

name:MethylprednisoloneAndAntiinfectives
ATC code:S01CA08
route:
compartments:0
dosage:1mg
volume of distribution:1L
clearance:0
other parameters in model implementation

Methylprednisolone and antiinfectives (ATC S01CA08) is a combination ocular drug preparation intended for the treatment of eye infections and inflammation. Methylprednisolone is a corticosteroid used for its anti-inflammatory and immunosuppressive properties, while the antiinfective component prevents or treats bacterial infections. This combination is primarily used in ophthalmology to manage inflammatory eye conditions with a concurrent risk or presence of infection. Not all countries have this specific combination approved, and its availability may vary.

Pharmacokinetics

No pharmacokinetic studies or published PK models specific to the combined preparation of methylprednisolone and antiinfectives (S01CA08) for ophthalmic use were identified in the literature. Thus, PK parameter values are not directly available.

References

  1. Suetsugu, K, et al., & Ieiri, I (2021). Effects of Letermovir and/or Methylprednisolone Coadministration on Voriconazole Pharmacokinetics in Hematopoietic Stem Cell Transplantation: A Population Pharmacokinetic Study. Drugs in R&D 21(4) 419–429. DOI:10.1007/s40268-021-00365-0 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34655050

  2. Wu, Y, et al., & Liu, T (2025). Drug-drug interaction of phenytoin sodium and methylprednisolone on voriconazole: a population pharmacokinetic model in children with thalassemia undergoing allogeneic hematopoietic stem cell transplantation. European journal of clinical pharmacology 81(3) 365–374. DOI:10.1007/s00228-024-03795-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39714727

  3. Hodel, K, et al., & Godoy, AL (2024). Obesity and its Relationship with Covid-19: A Review of the Main Pharmaceutical Aspects. Current pharmaceutical biotechnology 25(13) 1651–1663. DOI:10.2174/0113892010264503231108070917 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38258769

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)